Abstract

Examination of early phases of synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development of disease modifying therapies. The rat alpha-synuclein (α-syn) preformed fibril (PFF) model induces synchronized synucleinopathy that recapitulates the pathological features of Parkinson’s disease (PD) and can be used to study synucleinopathy progression. In this model, phosphorylated α-syn (pSyn) inclusion-containing neurons and reactive microglia (major histocompatibility complex-II immunoreactive) peak in the substantia nigra pars compacta (SNpc) months before appreciable neurodegeneration. However, it remains unclear which specific genes are driving these phenotypic changes. To identify transcriptional changes associated with early synucleinopathy, we used laser capture microdissection of the SNpc paired with RNA sequencing (RNASeq). Precision collection of the SNpc allowed for the assessment of differential transcript expression in the nigral dopamine neurons and proximal glia. Transcripts upregulated in early synucleinopathy were mainly associated with an immune response, whereas transcripts downregulated were associated with neurotransmission and the dopamine pathway. A subset of 29 transcripts associated with neurotransmission/vesicular release and the dopamine pathway were verified in a separate cohort of males and females to confirm reproducibility. Within this subset, fluorescent in situ hybridization (FISH) was used to localize decreases in the Syt1 and Slc6a3 transcripts to pSyn inclusion-containing neurons. Identification of transcriptional changes in early synucleinopathy provides insight into the molecular mechanisms driving neurodegeneration.

Details

Title
Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils
Author
Patterson, Joseph R. 1   VIAFID ORCID Logo  ; Kochmanski, Joseph 2   VIAFID ORCID Logo  ; Stoll, Anna C. 3 ; Kubik, Michael 1 ; Kemp, Christopher J. 2 ; Duffy, Megan F. 1   VIAFID ORCID Logo  ; Thompson, Kajene 2 ; Howe, Jacob W. 1   VIAFID ORCID Logo  ; Cole-Strauss, Allyson 2 ; Kuhn, Nathan C. 2 ; Miller, Kathryn M. 1 ; Nelson, Seth 2 ; Onyekpe, Christopher U. 2 ; Beck, John S. 2 ; Counts, Scott E. 1 ; Bernstein, Alison I. 4   VIAFID ORCID Logo  ; Steece-Collier, Kathy 2 ; Luk, Kelvin C. 5   VIAFID ORCID Logo  ; Sortwell, Caryl E. 1 

 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Michigan State University, Neuroscience Program, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501) 
 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501) 
 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Michigan State University, Department of Pharmacology and Toxicology, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501) 
 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Rutgers University, Department of Pharmacology and Toxicology, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Environmental and Occupational Health Science Institute, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
 University of Pennsylvania Perelman School of Medicine, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
Pages
7
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2909354043
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.